The global familial amyloid polyneuropathy market is projected to witness significant growth from 2021 to 2031 (forecast period). The growing incidence of familial amyloid polyneuropathy in emerging nations is expected to drive the global market during the forecast period. This is a fairly uncommon condition that is often inherited.
The disease's incidence rate is anticipated to be significantly lower in developed nations such as the United States and many other European nations. In other parts of the world, the incidence is much higher.
The increasing awareness regarding the condition is projected to boost the global familial amyloid polyneuropathy market. Moreover, the advent of new therapies is expected to present lucrative opportunities for the global familial amyloid polyneuropathy market growth.
Some of the prominent players active in the global familial amyloid polyneuropathy market are Ionis Pharmaceuticals Inc., Pfizer Inc., Alnylam Pharmaceuticals Inc., Proclara Biosciences, Corino Therapeutics Inc., Arcturus Therapeutics Inc., and others.
A large number of companies from all over the world operate in the worldwide familial amyloid polyneuropathy market. They are primarily engaged in research and development operations to create novel familial amyloid polyneuropathy treatments to meet the growing demand from the patient population. Since it is an uncommon condition, treatment options are limited. As a result, producing new pharmaceuticals is expected to assist companies in increasing sales. Several firms intend to work on developing cost-effective products or services in order to establish a strong market position.
The global familial amyloid polyneuropathy market is projected to witness considerable growth during the forecast period. Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are rare autosomal dominant disorders induced by protein and amyloid fibril deposition around peripheral nerves and numerous tissues such as the heart muscle. In the case of peripheral neuropathy, symptoms involve limb weakness and loss of sensation; in the case of autonomic neuropathy, symptoms involve bowel difficulty and sexual dysfunction. The most effective therapy for the condition is a liver transplant; however, Europe has approved a medicine called Vyndaqel (tafamidis) by Pfizer Inc., which is currently in Phase III clinical trials to gain FDA clearance in the United States.
The development of new medications for the treatment of familial amyloid polyneuropathy and an increase in the disease's occurrence is likely to boost the global familial amyloid polyneuropathy market. Moreover, increased drug acceptance for familial amyloid polyneuropathy and developing nations such as India, China, and others are expected to provide new avenues for the worldwide familial amyloid polyneuropathy market.
Furthermore, the growing number of companies active in the market is expected to create more profitable growth opportunities. Such factors are anticipated to boost the global familial amyloid polyneuropathy market during the forecast period.
The familial amyloid polyneuropathy market in Asia Pacific is expected to grow during the forecast period. The regional market is likely to gain from the increasing frequency of familial amyloid polyneuropathy illness in several Asia Pacific countries.
The North America familial amyloid polyneuropathy market is projected to experience growth, owing to the increasing number of industry players active in the region. The United States is expected to make considerable contribution to the familial amyloid polyneuropathy market in North America.
The familial amyloid polyneuropathy market in Latin America and the Middle East and Africa is anticipated to expand during the forecast period. This is due to increased public awareness of the many potential advantages of familial amyloid polyneuropathy treatments and a greater rate of drug adoption in these regions.